2026

Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026 Vancouver, British Columbia and Rehovot, Israel— (May 12, 2026) – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a leader in Botanical Synthesis technology

Ilan Sobel joins Board of Directors with focused mandate on D2C growth.Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumes role of Chief Executive Officer, Integrating R&D, Manufacturing, and Operations under the CDMO. Vancouver, British Columbia and Rehovot, Israel – April 29, 2026 – BioHarvest Sciences Inc. (Nasdaq: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a

CDMO division has successfully completed Stage 1 under a development contract Vancouver, British Columbia and Rehovot, Israel – March 31, 2026 — BioHarvest Sciences Inc. (“BioHarvest” or the “Company”), (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has successfully completed Stage 1

FY2025 Revenues were $34.5 million,  up 37% vs previous year. The VINIA brand has achieved the  No.1 resveratrol polyphenol position in the United States Market*. Successful 4Q2025 Institutional-led Financing raised gross proceeds of an oversubscribed  $19.9 million. Cash and cash equivalents of $23 million as of December 31, 2025. Vancouver, British Columbia and Rehovot, Israel

VINIA’s leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest’s Botanical Synthesis platform technology March 26, 2026 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”), (Nasdaq: BHST) (FSE: 8MV0), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved